Therapeutic potential of culinary-medicinal mushrooms for the management of neurodegenerative diseases: diversity, metabolite, and mechanism

Chia-Wei Phan$^{1,2}$, Pamela David$^{1,3}$, Murali Naidu$^{1,3}$, Kah-Hui Wong$^{1,3}$, and Vikineswary Sabaratnam$^{1,2}$

$^1$Mushroom Research Centre, Institute of Biological Sciences, Faculty of Science, University of Malaya, Kuala Lumpur, Malaysia, $^2$Institute of Biological Sciences, Faculty of Science, University of Malaya, Kuala Lumpur, Malaysia, and $^3$Department of Anatomy, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia

Abstract
Mushrooms have long been used not only as food but also for the treatment of various ailments. Although at its infancy, accumulated evidence suggested that culinary-medicinal mushrooms may play an important role in the prevention of many age-associated neurological dysfunctions, including Alzheimer’s and Parkinson’s diseases. Therefore, efforts have been devoted to a search for more mushroom species that may improve memory and cognition functions. Such mushrooms include Hericium erinaceus, Ganoderma lucidum, Sarcodon spp., Antrodia camphorata, Pleurotus giganteus, Lignosus rhinocerotis, Grifola frondosa, and many more. Here, we review over 20 different brain-improving culinary-medicinal mushrooms and at least 80 different bioactive secondary metabolites isolated from them. The mushrooms (either extracts from basidiocarps/mycelia or isolated compounds) reduced beta amyloid-induced neurotoxicity and had anti-acetylcholinesterase, neurite outgrowth stimulation, nerve growth factor (NGF) synthesis, neuroprotective, antioxidant, and anti-(neuro)inflammatory effects. The in vitro and in vivo studies on the molecular mechanisms responsible for the bioactive effects of mushrooms are also discussed. Mushrooms can be considered as useful therapeutic agents in the management and/or treatment of neurodegeneration diseases. However, this review focuses on in vitro evidence and clinical trials with humans are needed.

Keywords
Alzheimer's disease, antioxidant, culinary-medicinal mushroom, neurite outgrowth, nerve regeneration, neurodegeneration, neuroprotection, secondary metabolite

Introduction
Life expectancy of humankind had increased to 50–60 years at the beginning of the twentieth century due to improved medicinal, dietary, and sanitation conditions. It is, however, foreseen that society will witness an elevated life expectancy of 80–90 years by the twenty-first century (Candore et al., 2006). Nevertheless, ageing is inexorable with an age-associated decline in immune competence and the onset of chronic inflammation leading to neurodegenerative diseases including dementia, Alzheimer’s disease (AD) and Parkinson’s disease (PD); atherosclerosis and stroke; diabetes; sarcopenia; and cancer (Martorana et al., 2012). With the increased lifespan of the world’s population, it is estimated that about 80 million people will suffer from dementia by 2040 whereby AD accounted for almost 60% of dementia cases (Bharadwaj et al., 2010).

The pathological hallmarks of AD are characterised by amyloidogenic processing of amyloid precursor protein (APP) and a subsequent β-amyloid cascade and tau hyperphosphorylation (Claeyssen et al., 2012). Other hypotheses of AD pathogenesis include microglial activation associated with neuroinflammation, increased level of acetyl cholinesterase (AChE) activity, and free radical generation (Martorana et al., 2012). Drug therapies for AD include nicotine, melatonin, estrogens (Côté et al., 2012) cholinesterase inhibitors, and an N-methyl-D-aspartate receptor antagonist named memantine (Hong-Qi et al., 2012). However, the current AD drug therapy is ineffective and only provides a short-term delay progression of AD. Moreover, although there was a close association of the use of non-steroidal anti-inflammatory drugs (NSAIDs) and a lower incidence of AD, patients suffered from withdrawal syndrome as a result of gastrointestinal toxicity (Hong-Qi et al., 2012).

There has been a recent upsurge of interest in complementary and alternative medicine, especially dietary supplements and functional foods in delaying the onset of age-associated neurodegenerative diseases. As recently reviewed by Perry & Howes (2011), phyto-chemical approach for dementia and AD treatment includes galantamine from Narcissus sp., lemon balm (Melissa officinalis), and periwinkle (Vinca minor). Other edible “brain food” consists primarily of blueberry, grape seed, pomegranate, and walnut. The polyphenol entities found in the vegetables,
Mushrooms offer great potential as a polypharmaceutic drug because of the complexity of their chemical contents and different varieties of bioactivities. Available evidence suggests that mushrooms exhibit anti-oxidants, anti-tumor, anti-virus, anti-cancer, anti-inflammatory, immune modulating, anti-microbial, and anti-diabetic activities (Roupas et al., 2012). In contrast to plant herbal medicines, which are widely explored and relatively more advanced, the brain and cognition health effects of mushrooms are in the early stages of research. Palmitic, oleic, and linoleic acids dominate fatty acid profiles in mushrooms (Doğan & Akbaş, 2013). These fatty acids are important nutritionally, as oleic acid (C18:1 n-9) has been shown to promote axon generation in the striatum during brain development (Guest et al., 2013). Furthermore, in vitro toxicology assessment across different mushroom extracts on embryonic fibroblast and neuroblastoma cell lines suggested that the extracts are safe to be consumed even at high doses and they may be developed as a dietary supplement to improve brain and cognitive health. An elaborated discussion on the toxicity of various mushroom metabolites can be found in Phan et al. (2013).

Disease prevention is better than cure especially in neurodegenerative diseases as degeneration process is nearly impossible to be arrested or delayed once the process has commenced. In the present review, brain and cognition health effects of higher Basidiomycetes are analyzed with emphasis on dementia, AD, and PD. The review summarizes the biodiversity of brain-health promoting mushrooms, the chemical structure of the responsible bioactive metabolites, their biological actions, and molecular mechanisms, i.e. neurite outgrowth, cholinesterase inhibition, BACE1 inhibition, anti-neuroinflammation and neuroprotection. The positive, as well as negative, results of experimental testing (in vitro and in vivo) are also included.

Diversity of mushrooms with brain health promoting effects

In mushroom biology, species boundaries are always indistinct and many mushrooms are subsumed under erroneous names (Hallenberg et al., 2012). Therefore, common names and taxonomic descriptions of different culinary-medicinal mushrooms, which were found to promote brain and cognitive health, are included in Supplemental Table 1. Common names and a morphological description of the mushroom basidiocarps can also be found in Supplemental Table 1.

Inhibition of beta-amyloid, p-tau, and acetylcholinesterase

Beta-amyloid 1–42 (Aβ1–42), a 42-amino acid-length polypeptide, is a cleavage product of amyloid precursor protein (APP) by two secretase enzymes: beta (β-) and gamma (γ-) secretases. Aβ peptides self assemble into soluble oligomers and deposit as insoluble senile plaque in the hippocampus; causing impaired memory and cholinergic dysfunctions in the brains of Alzheimer’s patients. Therefore, AD may be prevented by inhibiting the production of Aβ or preventing the aggregation of Aβ into amyloid plaques. Following this hypothesis, the potential of β-secretase (β-site APP cleaving enzyme, BACE1) inhibitor is promising (Sabotic & Kos, 2012). Some BACE1 (EC3.4.23.46) inhibitors such as KMI-429, GSK188909, and PMS777 have provided new insights for clinical application in the near future (Sathya et al., 2012). Apart from that, the level of acetylcholine, a neurotransmitter involved in the regulation of learning and memory functions, decreased dramatically in the neocortex and hippocampus in AD. Therefore, AChE inhibitors can be used to restore acetylcholine levels and therefore cholinergic brain activity.

Aβ 1–40 causes oxidative stress and inflammation in the brain leading to the secretion of p-tau protein which is involved in neuron damage (Bharadwaj et al., 2010). In a study by Wang et al. (2012), the mycelium and/or fruiting body of Antrodia camphorata were able to reverse the damaging effects of in vivo Aβ-40 infusion and in vitro Aβ-40 treatment. A working memory test to evaluate short-term memory and learning abilities of Aβ brain infusion rats was carried out. The mushroom-supplemented group displayed better improvement in memory and learning abilities. Also, the expression of p-tau protein in rat pheochromocytoma (PC-12) cells was significantly decreased by the treatment of A. camphorata. However, A. camphorata did not have significant inhibitory effects on BACE expression. This result was interpreted to indicate that p-tau inhibition, rather than BACE modulation, played a vital role in AD prevention by A. camphorata.

The effects of Hericium erinaceus on Aβ25–35 peptide-induced cognitive dysfunction in mice was investigated by Mori et al. (2011). The powder of H. erinaceus was mixed with a normal powdered diet and the Aβ25–35 peptide was administered by intracerebroventricular injection. The results revealed that H. erinaceus prevented impairments of spatial short-term and visual recognition memory induced by Aβ25–35 in mice. Human trials with H. erinaceum derivatives also showed promising results in patients with dementia based on Revised Hasegawa Dementia Scale (HDS-R) (Mori et al., 2009).

Aqueous extract of Ganoderma lucidum significantly attenuated Aβ-induced synaptotoxicity and apoptosis by preserving the synaptic density protein called synaptophysin (Lai et al., 2008). Further, a study by Wang et al. (2004) concluded that senescence-accelerated mice (strain SAMP8) given a diet supplemented with Ganoderma extract exhibited significantly lower brain amyloid and higher antioxidant activities such as superoxide dismutase, glutathione peroxidase (GPx), and glutathione reductase when compared with the control mice. Moreover, a study by Pinweha et al. (2008) suggested that G. lucidum mycelium extract might possess nerve growth factor (NGF)-like properties for the processing of APP via an enhanced NGF signaling pathway. As a result, the increased APP expression promoted non-amyloidogenic protein secretion (sAPP).

The mushroom Cortinarius infracus has a strong bitter taste and an unpleasant odor due to the presence of indole alkaloids infractine, 6-hydroxyinfracine, and infractopicine (Bordon et al., 2007). Infracopicin (1) and 10-hydroxy-infracopicin (2) (Supplemental Figure 1) showed AChE-inhibiting activity with non-detectable cytotoxicity (Geissler et al., 2010). Topological polar surface area (TPSA) of below
70 Å² suggested that the compounds could pass through the blood–brain barrier. Aggregation of Aβ1–40 (fibril formation) was also inhibited by the two alkaloids as revealed by the thioflavin T fluorescence assay. In addition, in vitro AChE and butyrylcholinesterase-inhibiting activities of extracts of Tricholoma species (T. fructicum, T. imbricatum, and T. terreum) were tested. As a result, only the hexane extract of T. imbricatum (0.2 mg/mL) was confirmed to inhibit AChE and butyrylcholinesterase by 71.8 ± 0.3% and 52.6 ± 1.0%, respectively (Tel et al., 2011).

According to Dai et al. (2010), hispidin (3), a class of polyphenols, is an important medicinal metabolite from Phellinus spp. Hispidin (Supplemental Figure 1) was isolated from the culture broth of P. linteus, and it has been shown to be a non-competitive inhibitor of BACE1 with an IC₅₀ value of 4.9 × 10⁻⁶ M and a Kᵢ value of 8.4 × 10⁻⁶ M (Park et al., 2004a). In addition, hispidin was shown to be an efficient reactive oxygen species (ROS) scavenger (Park et al., 2004b). Agaricus bisporus (button mushroom), Flammulina velutipes (enoki), and Lentinula edodes (shimeji) neither inhibited nor activated BACE1. The major polysaccharide of button mushroom, β-D-glucan, in contrast, did not cause BACE1 activation (Sheean et al., 2012). The results indicated that BACE1 activity behaved differently with different compound features. Nevertheless, the effects of button mushrooms, enoki, and shimeji together with β-D-glucan need to be tested further. Most recently, BACE1 activity was shown to be inhibited by extracts of fresh basidiocarps of Auricularia polytricha (wood ear mushroom). The BACE1 inhibitory activity was most likely due to the hispidin-derived polyphenolics (Bennett et al., 2013b).

**Stimulation of neurite outgrowth and NGF synthesis**

Neurotrophic factors (neurotrophins) such as NGF, brain-derived neurotrophic factor (BDNF), neurotrophin 3 (NT-3), and glia-derived neurotrophic factor (GDNF) play an important role in differentiation, survival, and maintenance of the neuronal cells. Insufficient neurotrophins is believed to result in dysfunction of the nervous system, causing dementia, AD, and PD. However, polypeptides such as NGF in therapy are unfavorable as they are unable to cross the blood–brain barrier. Therefore, finding small molecules that show neurotrophic properties and/or enhancing the action of endogenous neurotrophic factors is important (Shi et al., 2011).

Sarcodon spp., also called “bitter tooth”, are widely distributed in Europe, North America, and Asia. Sarcodon mushrooms are considered inedible due to their bitter taste. On one hand, cyrneines A (4) and B (5) (Figure 1) isolated from Sarcodon cyrneus stimulated neurite outgrowth in PC12 at 100 μM with no cytotoxicity as indicated by lactate dehydrogenase (LDH) analysis (Marcotullio et al., 2006a) (Table 1). Later, it was shown that both cyrneines A and B promoted NGF production in 1321N1 cells (Marcotullio et al., 2007). Neurite outgrowth activity was observed in NG108-15 cells, a hybrid neuronal cell line derived from mouse neuroblastoma and rat glioma (Obara et al., 2007). On the other hand, cyrneines C (6) and D (7) failed to induce neurite outgrowth. In addition, glaucopine C (8), isolated from the hexane extract of Sarcodon glaucopus (Marcotullio et al., 2006b), did not significantly promote neurite outgrowth in PC12 cells but induced NGF gene expression to a lesser extent when compared with cyrneines A and B. It seemed that the presence of the hydroxyl cyclohexadienyl carbaldehyde system in cyrneines could be important for neuritogenesis (Marcotullio et al., 2007). In other words, minor differences in functional groups on cyathane structures in cyrneines A, B, C, and D can influence the responses in neuronal cells. Figure 1 shows the chemical structure of different cyrneines.

Scabronine A (9) (Table 2), isolated from Sarcodon scabrosus, showed potent inductive activity of NGF synthesis in 1321N1 human astrocytoma cells (Ohta et al., 1998). Further investigation led to the isolation of novel cyathane diterpenoids named scabronines B–F (10–14) (Kita et al., 1998), G (15) (Obara et al., 1999), K (16), and L (17) (Shi et al., 2011). However, only scabronines B, C, E, and G showed NGF-synthesis stimulating activity. It appeared that the presence of the α,β-unsaturated aldehyde system in the seven-membered ring could be crucial for the bioactivity. Recently, the first synthesis of scabronine G in optically pure form has been reported, and the neurite outgrowth activity was comparable with NGF and natural scabronine G (Waters et al., 2005). Meanwhile, scabronine G-methyl-ester (18) synthesized from scabronine G also potently promoted the secretion of NGF and interleukin-6 (IL-6), another major neurotrophic factor released from astrocytes. Most recently, secoscabronine M (19), a hemiacetal cyathane diterpenoid was isolated from S. scabrosus but no neuritogenesis has been reported for this compound. Figure 1 shows the structures of scabronine A-G, K, L, scabronine G-methyl-ester, and secoscabronine M isolated from S. scabrosus.

There is a possible use of Hericium erinaceus (Bull.: Fr.) Pers. in the treatment of neurological disorders and dementia as reported by Kawagishi & Zhuang (2008). In a study by Wong et al. (2007), the extracts of H. erinaceus fruiting body and mycelium induced neurite outgrowth of neuronal cells NG108-15 in vitro (Supplemental Figure 2). Also, ethanol extract of H. erinaceus promoted the neurite outgrowth of PC12 cells, enhanced NGF mRNA expression, and the secretion of NGF from 1321N1 human astrocytoma cells (Mori et al., 2008). Further, in vivo functional recovery of axonometric peroneal nerve injury in Sprague–Dawley rats was assessed by walking-track analysis and toe-spreading reflex (Wong et al., 2009) (Supplemental Figure 3). The peroneal functional index (PFI) and toe-spreading reflex improved more rapidly in the group treated with daily administration of H. erinaceus extract. These data suggested that H. erinaceus could promote the regeneration of nerve injury in the early stage of recovery (Wong et al., 2010). Although preliminary, it was demonstrated that the H. erinaceus extract exerted neurotrophic action and improved the myelination process in the rat brain without affecting nerve cell growth and toxicity (Moldavan et al., 2007). There was an attempt to isolate a polysaccharide from the mycelium of H. erinaceus and the polysaccharide (1 000 000 dalton; molar ratio of 1.5:1.7:1.2:0.6:0.9; glucose:galactose:xylene:mannose:fructose) promoted neurite outgrowth in PC12 cells in vitro (Park et al., 2002).
However, it needs to be clarified that this in vitro evidence cannot be assumed to occur in vivo and that the in vitro activity of polysaccharides cannot be extrapolated to explain in vivo observations.

On one hand, hericenones (benzyl alcohol derivatives) were isolated from the fruiting bodies of *H. erinaceus* (Table 2). Hericenones A (20) and B (21) were first reported in 1990 but no neurite outgrowth activity was reported (Kawagishi et al., 1990). Hericenones C (22), D (23), E (24), F (25), G (26), and H (27) exhibited stimulating activity for the biosynthesis of NGF in vitro (Kawagishi & Ando, 1993; Kawagishi et al., 1991). On the other hand, diterpenoid derivatives (named erinacines) were isolated from the mycelium of *H. erinaceus*. Erinacines A–I (28–36) significantly induced the synthesis of NGF in vitro (Kawagishi et al., 1994, 1996a,b; Lee et al., 2000) and in vivo (Shimbo et al., 2005).
Table 1. Compounds isolated from mushroom Sarcodon spp. that were screened for neurite outgrowth activity.

| No. | Compound       | Sarcodon spp. | In vitro study       | Neurite outgrowth activity          | References                              |
|-----|----------------|----------------|----------------------|-------------------------------------|-----------------------------------------|
| 4   | Cyrneine A     | SC             | PC12; NG108–15; 1321N1 | Neurite outgrowth ↑, NGF ↑          | Marcotullio et al. (2006a) and Obara et al. (2007) |
| 5   | Cyrneine B     | SC             | PC12                 | Neurite outgrowth ↑, NGF ↑          | Marcotullio et al. (2006b, 2007)        |
| 6   | Cyrneine C     | SC             | PC12                 | –                                   | Marcotullio et al. (2007)               |
| 7   | Cyrneine D     | SC             | PC12                 | –                                   | Marcotullio et al. (2007)               |
| 8   | Glauconicine C | SG             | PC12                 | NGF gene expression ↑               | Marcotullio et al. (2006a) and Marcotullio et al. (2007) |
| 9   | Scabronine A   | SS             | 1321N1               | Neurite outgrowth ↑                 | Ohta et al. (1998)                      |
| 10  | Scabronine B   | SS             | Rat astroglial cells | NGF ↑                               | Kita et al. (1998)                      |
| 11  | Scabronine C   | SS             | Rat astroglial cells | NGF ↑                               | Kita et al. (1998)                      |
| 12  | Scabronine D   | SS             | Rat astroglial cells | –                                   | Kita et al. (1998)                      |
| 13  | Scabronine E   | SS             | Rat astroglial cells | NGF ↑                               | Kita et al. (1998)                      |
| 14  | Scabronine F   | SS             | Rat astroglial cells | –                                   | Kita et al. (1998)                      |
| 15  | Scabronine G   | SS             | 1321N1               | Neurite outgrowth ↑                 | Obara et al. (1999) and Waters et al. (2005) |
| 16  | Scabronine G-Methyl ester | SS | PC12              | NGF and IL-6 ↑                      | Obara et al. (2001)                      |
| 17  | Scabronine K   | SS             | PC12                 | –                                   | Shi et al. (2011)                       |
| 18  | Scabronine L   | SS             | PC12                 | –                                   | Shi et al. (2011)                       |
| 19  | Secoscabronine M | SS       | –                    | –                                   | Shi et al. (2012)                       |

SC, S. cymneus; SG, S. glaucopus; SS, S. scabrosus; –, no effect on neurite outgrowth; NGF, nerve growth factor; ↑, promoted/increased.

Table 2. List of hericenones and erinacines in Hericium erinaceus, some of which showed neurite outgrowth activity.

| No. | Compound       | Mushroom component | In vitro study       | Neurite outgrowth activity          | References                              |
|-----|----------------|---------------------|----------------------|-------------------------------------|-----------------------------------------|
| 20  | Hericenone A   | F                   | –                    | –                                  | Kawagishi et al. (1990)                 |
| 21  | Hericenone B   | F                   | –                    | –                                  | Kawagishi et al. (1990)                 |
| 22  | Hericenone C   | F                   | Mouse astroglial cells | NGF ↑                             | Kawagishi et al. (1991)                 |
| 23  | Hericenone D   | F                   | Mouse astroglial cells | NGF ↑                             | Kawagishi et al. (1991)                 |
| 24  | Hericenone E   | F                   | Mouse astroglial cells | NGF ↑                             | Kawagishi et al. (1991)                 |
| 25  | Hericenone F   | F                   | Mouse astroglial cells | NGF ↑                             | Kawagishi & Ando (1993)                 |
| 26  | Hericenone G   | F                   | Mouse astroglial cells | NGF ↑                             | Kawagishi & Ando (1993)                 |
| 27  | Hericenone H   | F                   | Mouse astroglial cells | NGF ↑                             | Kawagishi & Ando (1993)                 |
| 28  | Erinacine A    | M                   | Mouse astroglial cells | NGF ↑; catecholamine ↑ in the CNS of rats | Kawagishi et al. (1994) |
| 29  | Erinacine B    | M                   | Mouse astroglial cells | NGF ↑                             | Kawagishi et al. (1994)                 |
| 30  | Erinacine C    | M                   | Mouse astroglial cells | NGF ↑                             | Kawagishi et al. (1994)                 |
| 31  | Erinacine D    | M                   | Mouse astroglial cells | NGF ↑                             | Kawagishi et al. (1996b)                |
| 32  | Erinacine E    | M                   | Mouse astroglial cells | NGF ↑                             | Kawagishi et al. (1996a)                |
| 33  | Erinacine F    | M                   | Mouse astroglial cells | NGF ↑                             | Kawagishi et al. (1996a)                |
| 34  | Erinacine G    | M                   | Mouse astroglial cells | NGF ↑                             | Kawagishi et al. (1996a)                |
| 35  | Erinacine H    | M                   | Rat astroglial cells  | NGF ↑                             | Lee et al. (2000)                       |
| 36  | Erinacine I    | M                   | Rat astroglial cells  | NGF ↑                             | Lee et al. (2000)                       |
| 37  | Erinacine J    | M                   | MRSA                 | –                                  | Kawagishi et al. (2006)                 |
| 38  | Erinacine K    | M                   | MRSA                 | –                                  | Kawagishi et al. (2006)                 |
| 39  | Erinacine P    | M                   | –                    | Biosynthesis of erinacines         | Kenmoku et al. (2000)                   |
| 40  | Erinacine Q    | M                   | –                    | Biosynthesis of erinacine C        | Kenmoku et al. (2002)                   |
| 41  | Erinacine R    | M                   | –                    | –                                  | Ma et al. (2010, 2008)                  |
| 42  | Erinacol       | M                   | –                    | –                                  | Kenmoku et al. (2004)                   |

F, fruiting body; M, mycelium; –, none; NGF, nerve growth factor; CNS, central nervous system; MRSA, methicillin-resistant Staphylococcus aureus.

Isolation of new compounds from this mushroom continued with the discovery of erinacines J (37), K (38), P–R (39–41), as well as erinacol (42), a novel cyathadien-14,3-ol (Kawagishi et al., 2006; Kenmoku et al., 2000; Kenmoku et al., 2002, 2004; Ma et al., 2010, 2008). Structures of hericenones and erinacines are given in Figure 2.

Cheung et al. (2000) reported that G. lucidum extract reduced PC12 cell proliferation and induced neuronal differentiation and neurite outgrowth via the activation of MAP kinases and cAMP-response element binding protein (CREB) signaling pathways. In addition, a lipophilic fraction of G. lucidum (125 and 500 mg/L) was also shown to induce neurite outgrowth of PC12 cells (Zhang et al., 2005).

Mycoleptodonoides aitchisonii is a rare mushroom that improves brain function in rats. The mycelium-containing cultivation medium was found to bear fragrant compounds of phenylpentane, which consists of 1-phenyl-3-pentanol and 1-phenyl-3-pentanone. The compounds improved dopamine liberation in the brains of rats fed with the mushroom powder or aqueous extracts (Okuyama et al., 2004a). Further, NGF synthesis in the cerebral cortex and hippocampus of newborn rats was also enhanced after the pregnant rats were fed...
with either *M. aitchisonii* powder or its aqueous extract for 7 d before delivery (Okuyama et al., 2004b). A recent study concluded that *M. aitchisonii* aqueous extract prevented the reduction of dopaminergic and serotonergic neuronal activities following brain ischemia damage in the cerebral cortex (Okuyama et al. 2012). The concentrations of the neurotransmitters, dopamine, and its metabolites were increased after treatment with this mushroom. Moreover, *M. aitchisonii* was shown to activate NF-E2-related factor 2 (Nrf2) and might contribute to the prevention of oxidative stress-related diseases (e.g. Alzheimer’s) by inducing antioxidative and phase II detoxifying enzyme series (Kokubo et al., 2011).

*Dictyophora indusiata* is a famous edible mushroom used in Chinese cuisine and medicine. Two eudesmane-type sesquiterpenes, dictyophorines A (43) and B (44) (Supplemental Figure 4), were isolated from the mushroom and were found to promote NGF synthesis by astroglial cells (Kawagishi et al., 1997). It was shown that NGF secreted into the medium in the presence of 3.3 mM of dictyophorines A was four times higher than the negative control. Meanwhile, lysophosphatidylethanolamine (LPE) isolated from *G. frondosa* (GLPE) was found to induce neurite outgrowth and it upregulated the neurofilament M expression in cultured PC12 cells (Nishina et al., 2006). This study also showed the suppressive effect of *G. frondosa* on serum deprivation-induced apoptosis of the PC12 cells.

The aqueous extract of *Tremella fuciformis* not only promoted neurite outgrowth of the PC12 cells but also significantly reversed the scopolamine- and trimethyltin-induced memory deficit in rats, as revealed by the Morris water maze test and choline acetyltransferase (ChAT) immunohistochemistry (Kim et al., 2007; Park et al., 2012). Besides, neuritogenic compounds named tricholomalides A–C (45–47) (Supplemental Figure 4) were also isolated from *Tricholoma* sp. and neurite outgrowth in PC-12 cells was significantly induced at concentrations of 100 μM (Tsukamoto et al., 2003). Whereas for *Termitomyces*
For personal use only.

Critical Reviews in Biotechnology Downloaded from informahealthcare.com by Library of Health Sci-Univ of Il on 05/29/14

region) is currently being explored. A study by Zhu et al. (2005) has shown that rats fed with G. lucidum spores oil ameliorated Parkinsonism induced by neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). The number of surviving dopamine neurons in the substantia nigra and the level of dopamine in the striatum of MPTP-induced mice has increased after treatment with the oil of Ganoderma spores. Furthermore, involuntary movement of mice was also significantly reduced. Microglia is the resident innate immune cells of central nervous system (CNS) and it plays a major role in the neuroinflammatory process. Activation of microglia can trigger neurotoxicity via the production of pro-inflammatory and cytotoxic factors including tumor necrosis factor-(TNF)-α, nitric oxide (NO), superoxide radicals, interleukin-β (IL-β), and cyclooxygenase 2 (COX2) (Liu et al., 2006). The over-activation of microglia in the CNS contributes to neurodegenerative processes (Brown & Neher, 2010). To test for the potential neuroprotective effect of G. lucidum, co-cultures of 1-methyl-4-phenylpyridinium-(MPP⁺)-treated dopaminergic neuronal cell line MES23.5 and LPS-activated microglia were used (Zhang et al., 2011a). MPP⁺ is a metabolite of the neurotoxin MPTP. The G. lucidum extracts significantly inhibited the production of microglia-derived proinflammatory and cytotoxic factors (NO, TNF-α, and IL-1β) suggesting that G. lucidum is a promising agent in deterring inflammation-induced Parkinson’s disease.

Ganoderic acid is a member of highly oxygenated C₃₀ lanostane-type triterpenoids. However, its biological activity on the nervous system is still unknown. Recently, a new lanostanoid, 4,4,14-trimethyl-5-chol-7,9(11)-dien-3-oxo-24-oic acid (56) was isolated from an ethyl acetate extract of the dried fruiting bodies of G. lucidum. The triterpenoids, together with seven other known triterpenoids, i.e. 7-oxo-ganoderic acid Z (57), ganolucidic acid TQ (60), methyl ganoderic acid A (58), ganoderic acid S1 (61), ganodermic acid TQ (62) and ganodermatriol (63) (Figure 3), have shown NGF- and brain-derived neurotrophic factor-like neuronal survival-promoting effects (Table 3).

The role of vitamin D2-enriched button mushrooms (Agaricus bisporus) was studied especially for their memory improving effects in rats (Bennett et al., 2013a). Fungi, especially the members of Basidiomycetes, are rich in ergosterol. The ergosterol in mushrooms can be converted to vitamin D2 following exposure to ultraviolet (UV) light. Recent research suggested that higher vitamin D dietary intake was associated with a lower risk of developing AD among older women (Annweiler et al., 2012). Compound (56) has a steroidal feature resembling cholesterol that can be converted to vitamin D by enzymatic pathways, in response to UV irradiation. Therefore, there is a potential for this class of compounds to interact with vitamin D receptors and exert bioactivity via vitamin D mimicry.

The endoplasmic reticulum (ER) is an organelle within fungal cells in which protein folding, lipid biosynthesis, and calcium storage takes place (Brown & Naidoo, 2012). The ER, by serving as quality control machinery, suppresses protein aggregation in the cells under normal physiological
Figure 3. New lanostanoid (56), 7-oxo-ganoderic acid Z (57), ganolucidic acid A (58), methyl ganoderic acid A (59), methyl ganoderic acid B (60), ganoderic acid S1 (61), ganoderic acid TQ (62), and ganodermatriol (63), isolated from *Ganoderma lucidum.*

| No. | Mushroom                  | Compound                                               | Neuronal surviving effect | References                      |
|-----|---------------------------|--------------------------------------------------------|---------------------------|--------------------------------|
| 56  | *Hericium erinaceum*      | 4,4,14-Trimethyl-5-chol-7,9(11)-dien-3-oxo-24-oic acid | NGF                       | Zhang et al. (2011b)           |
| 57  |                           | 7-Oxoganoderic acid Z                                  | BDNF                      | Li et al. (2006) and Zhang et al. (2011b) |
| 58  |                           | Ganolucidic acid A                                     | BDNF                      | Zhang et al. (2011b)           |
| 59  |                           | Methyl ganoderic acid A                                | BDNF                      | Zhang et al. (2011b)           |
| 60  |                           | Methyl ganoderic acid B                                | NGF                       | Zhang et al. (2011b)           |
| 61  |                           | Ganoderic acid S1                                      | BDNF                      | Zhang et al. (2011b)           |
| 62  |                           | Ganoderic acid TQ                                      | BDNF                      | Zhang et al. (2011b)           |
| 63  |                           | Ganodermatriol                                         | BDNF                      | Zhang et al. (2011b)           |

NGF, nerve growth factor; BDNF, brain-derived neurotrophic factor.

Table 3. List of ganoderic acids in *Ganoderma lucidum* which showed neuroprotection effects in *in vitro* studies using NIH-3T3/TrkA and NIH-3T3/TrkB cells.

conditions. However, with age and under stress, ER homeostasis will be interrupted and brings about the ER-stress response or the activation of the unfolded protein response, followed by programmed cell death (apoptosis) in the brain and/or insoluble protein fibrils formation. ER stress accompanies and contributes to several neurological disorders including PD. Due to that, the demand for new protective substances against the ER-stress-dependent cell death is high. In this review, the protective effects of medicinal mushrooms, namely *H. erinaceus*, *Stropharia rugosoannulata*, *Leccinum extremiorientale*, *Termitomyces titanicus*, and *Mycoleptodonoides aitchisonii* against age-implicated ER stress are discussed (Table 4).

In the protection assay against ER stress-dependent cell death, a popular cell line Neuro2a (N2a) cell is widely used. In general, the ER stress was either induced by addition of tunicamycin or thapsigargin. Tunicamycin is a protein glycosylation inhibitor that induces accumulation of misfolded protein in the ER and ultimately causes cell death. Thapsigargin is a non-competitive inhibitor of Ca\(^{2+}\) ATPase in ER that causes Ca\(^{2+}\) reduction. 3-hydroxyhericenone F (64) (Supplemental Figure 5), which was isolated from the fresh fruiting bodies of *H. erinaceus*, was found to protect N2a cells against both tunicamycin and thapsigargin toxicities (Ueda et al., 2008). Another ER stress attenuating compound, dilinoleoyl-phosphatidylethanolamine, was also isolated and
identified from the dried fruiting bodies of *H. erinaceum* (Nagai et al., 2006). A compound from *S. rugosoannulata* attenuated the ER stress caused by thapsigargin, but not by tunicamycin (Wu et al., 2011). The compound was later found to be strophasterol (65) with a new steroidal skeleton not previously reported (Wu et al., 2012) (Supplemental Figure 5). Similarly, leccinane A (66) (Supplemental Figure 5) from *L. extremiorientale* also showed significant protective activity against thapsigargin toxicity but not tunicamycin (Choi et al., 2011). Meanwhile, five fatty acid amides, termitomycamides A–E (67–71) isolated from *T. titanicus* (Supplemental Figure 5), were screened for their protective effects against tunicamycin toxicity. Only termitomycamides B and E showed significant protective effects, suggesting that these compounds blocked the inhibitory action of tunicamycin and N-linked glycosylation in ER was not repressed. Another four compounds (72–75) (Supplemental Figure 5) were also successfully isolated from the mushroom *M. aitchisonii* and they have shown attenuating effects on ER stress-dependant neuronal cell death (Choi et al., 2009).

*Inonotus obliquus* is another mushroom popular for its antioxidative effects in neuronal cells (Jung et al., 2008). An acid protein-bound polysaccharide from *I. obliquus* exhibited notable quenching of 1,1-diphenyl-2-picrylhydrazyl (DPPH) scavenging activities (Kim et al., 2011). Pepsin extracts of protease (Protamex) showed the highest DPPH radical-death in PC12 cells against H2O2-induced oxidative damage. *M. aitchisonii* (Figure 5) were also successfully isolated from the mushroom *L. extremiorientale* and they have shown attenuating effects on ER stress-dependant neuronal cell death (Choi et al., 2009).

**Mechanisms and signaling pathways of bioactivity of mushrooms secondary metabolites in neurodegenerative diseases**

Signal transduction cascades like the mitogen-activated protein kinase (MAPK), phosphatidylinositol-3-kinase-Akt (PI3K-Akt), and protein kinase C (PKC) pathways play important roles in neurons downstream of multiple signals including neurotrophins and neurotransmitters (Martin & Arthur, 2012). Certain mushrooms have shown NGF-like neuritogenic effects. Therefore, it is of utmost importance to elucidate the molecular mechanism responsible for the activity. Essentially, the process where a cell translates an external signal into cellular response is “signal transduction” (Martin & Arthur, 2012). Signal transduction begins with the binding of an external ligand (NGF, neurotransmitter, or mushroom compound in this case) to a specific receptor on a cell. This ultimately causes a systematic signalling cascade that initiates a response in a cell, for instance cell differentiation and extension of neurite.

The MAPK signal cascade is known to regulate cell growth and differentiation (Zhang & Liu, 2002). Three MAPK families have been characterized namely extracellular signal-regulated kinase (ERK), C-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK), and p38 kinase. Small and selective molecule protein kinase inhibitor is a powerful tool to study kinase function. Since NGF induces the activation of MEK and phosphorylation of ERK1/2, MEK inhibitors (U0126 and PD98059) were widely used as one of the checkpoints to assess the MAPK cascade. As reported by Phan et al. (2012), the induction of activation of ERK1/2 by both NGF and *P. giganteus* extracts was inhibited by U0126 and PD98059. Therefore, the mushroom extracts (as well as NGF) induced the activation of MEK1/2, resulting in neurite outgrowth. Similar observations were reported by Cheung et al. (2000) for *G. lucidium* extracts and Nishina et al. (2006), for lyso phosphatidylethanolamine from *Grifola frondosa*. Interestingly, there was no direct involvement of the Trk family of receptor tyrosine kinase, (TrkA) for the above mushroom-potentiated neuritogenesis, as opposed by the classical NGF. It is thus predicted that activation of TrkA may not be necessary for NGF-independent neuritogenic effects by mushrooms. It is widely accepted that PI3K/Akt regulates neuritogenesis (Kimura et al., 1994). Akt is a serine/threonine kinase essential for neurotrophin-induced cell survival and the activation of Akt by neurotrophins is
mediated by phosphatidylinositol-3 kinase (PI3K). Inhibition of PI3K/Akt by inhibitor LY294002 negatively affected neurite outgrowth of PC12 potentiated by *P. giganteus*. This finding suggested that *P. giganteus* induced-neurite outgrowth is also regulated by PI3K/Akt cascade.

As for the inhibitory mechanism of *G. lucidum* on Aβ25–35 neurotoxicity, the levels of stress kinases, namely phosphorylated JNK, phosphorylated c-Jun, and phosphorylated p38 were markedly attenuated (Lai et al., 2008). Meanwhile, the phosphorylation levels of ERK, JNK, and p38 were found to increase in microglia after lipopolysaccharide (LPS) and/or interferon gamma treatment. The methanol extracts of *A. camphorata* significantly inhibited the phosphorylation of ERK and JNK, slightly inhibited the activator of transcription (STAT-1) phosphorylation, in the course of anti-inflammatory activity in microglia. Another study also agreed that *A. camphorata* prevented serum deprivation-induced PC12 cell apoptosis through a PKA-dependent pathway and by suppression of JNK and p38 activities (Lu et al., 2008). 3,4-Dihydroxybenzalacetone (DBL) isolated from *I. obliquus*, inhibited H2O2-induced apoptosis of neurons by suppressing the intracellular ROS levels and inhibited Bax and caspase-3 activation. Treatment of DBL significantly inhibited the H2O2-dependent phosphorylation of p38-MAPK, but not the ERK and JNK, since p38 was responsible for phosphorylate p53, which ultimately lead to apoptosis.

IL-6 is an important interleukin to promote neuronal survival and neuronal differentiation. Scabronine G-ME-induced neuritogenesis was mediated by PKC cascades, since a selective inhibitor of PKC, GF109203X inhibited the process (Obara et al., 2001). In contrast, GF109203X, as well as the wortmannin (another inhibitor of PI3K), did not inhibit neurite outgrowth of PC12 in response to cyrneine A from the mushroom *Sarcodon cymneus*. This indicated that PKC and PI3K/Akt were not
involved. However, the neurite outgrowth process was blocked by PD98059, indicating that ERK1/2 is required for cyrnee A-induced neuritogenesis. The activity of Rac1, which is a GTPase protein that regulates actin, was also increased by cyrnee A. Both scabronine G-methylester and cyrnee A enhanced the activation of nuclear factor-XB, but not phospho-cAMP-response element-binding protein (CREB). In contrast to this, Tremella fuciformis (Park et al., 2012) and G. lucidum (Cheung et al., 2000) enhanced the neurite outgrowth of PC12 cells via activation of CREB transcription. A. camphorata was also found to prevent serum deprivation-induced PC12 cell apoptosis through CREB-dependent protein kinase A (PKA) pathway (Huang et al., 2005). The coordinated events involved in the mechanisms of antioxidant, anti-inflammation, neurite outgrowth, and inhibition of neurotoxicity are presented in Figure 4.

Conclusions

In this review, we have summarized mushrooms that have been reported to show beneficial effects in neuronal health, with particular emphasis on either crude extracts or isolated metabolites. Taken as a whole, these medicinal mushrooms have shown neurological properties such as neuronal survival and neurite outgrowth activities, including improvement in recovery and function in both in vitro and in vivo mammalian nervous systems. Therefore, based on the studies discussed in this review, including our own research over the last decade, we propose that these medicinal mushrooms may have therapeutic values to treat human neurological diseases. However, any such endeavor, involving human models, must be carried out with great care and caution as the pharmacological and negative effects of these mushrooms are not well established even though many of these mushrooms are edible. We hope this review will promote interest in medicinal mushroom research in the experimental clinical neurology area with a long-term objective of developing effective therapies for neurological diseases.

Acknowledgements

The authors thank University of Malaya for Postgraduate Research Grant (PV007/2012A). This review is supported by UM High Impact Research Grant UM-MOHE UM.C/625/1/HIR/MOHE/F00002-21001 from the Ministry of Higher Education Malaysia. We are deeply indebted to Prof. Roger Keynes, Department of Physiology, Neuroscience and Development, University of Cambridge, United Kingdom for reviewing the manuscript.

Declaration of interest

The authors report no conflicts of interest.

References

Anweiler C, Rolland Y, Schott AM, et al. (2012). Higher vitamin D dietary intake is associated with lower risk of Alzheimer’s disease: a 7-year follow-up. J Gerontol A Biol Sci Med Sci, 67, 1205–11.

Bennett L, Kersaitis C, Macaulay SL, et al. (2013a). Vitamin D2 -enriched button mushroom (Agaricus bisporus) improves memory in both wild type and APPsw/ePS1dE9 transgenic mice. PloS One, 8, e76362.

Bennett L, Sheean P, Zabaras D, Head R. (2013b). Heat-stable components of wood ear mushroom, Auricularia Polytricha (higher Basidiomycetes), inhibit in vitro activity of Beta Secretase (BACE1). Int J Med Mushrooms, 15, 233–49.

Bharadwaj P, Martins R, Macreadie I. (2010). Yeast as a model for studying Alzheimer’s disease. FEMS Yeast Res, 10, 961–9.

Biasirotti R, Tramontina AC, Costa AP, et al. (2013). Green tea (−) epigallocatechin-3-gallate reverses oxidative stress and reduces acetylcholinesterase activity in a streptozotocin-induced model of dementia. Behav Brain Res, 236, 186–93.

Brown J, Ekeberg D, Hötland K, et al. (2007). The real nature of the indole alkaloids in Cortinarius infractus: evaluation of artifact formation through solvent extraction method development. J Chromatogr A, 1148, 1–7.

Brown GC, Neher JJ. (2010). Inflammatory neurodegeneration and mechanisms of microglial killing of neurons. Mol Neurobiol, 41, 242–7.

Brown M K, Naidoo N. (2012). The endoplasmic reticulum stress response in aging and age-related diseases. Front Physiol, 3, 263.

Cook EA, Smith KM, Wingate D, et al. (2004). Dietary novel biogenic amines enhance cognitive performance in aged rats. J Nutr, 134, 2357–63.

Cui B-K, Dai Y-C, Zhou L-W, et al. (2010). Current advances in biochemical and pharmacological studies of triterpenoids from mushrooms. J Nat Prod, 73, 143–8.

Dai Y-C, Zhou L-W, Cui B-K, et al. (2010). Current advances in enforcement of artifact formation through solvent extraction method development. J Chromatogr A, 1148, 1–7.

Cuineau B, Rolland Y, Schott AM, et al. (2012). Higher vitamin D dietary intake is associated with lower risk of Alzheimer’s disease: a 7-year follow-up. J Gerontol A Biol Sci Med Sci, 67, 1205–11.

Dai Y-C, Zhou L-W, Cui B-K, et al. (2010). Current advances in enforcement of artifact formation through solvent extraction method development. J Chromatogr A, 1148, 1–7.

Geissler T, Brandt W, Porzel A, et al. (2010). Acetylcholinesterase inhibitors from the toadstool Cortinarius infractus. J Nat Prod, 69, 689–91.

Ghan A, Sultana R, Kaushik A, et al. (2007). Antioxidant and antiinflammatory activities of standardised preparations of plant- and microbial origin. Food Chem, 18, 2173–7.

Connolly JD, Hill RA. (2003). Triterpenoids. Nat Prod Rep, 20, 640.

Claeysen S, Cochet M, Donneger R, et al. (2012). Alzheimer culprits: cellular crossroads and interplay. Cell Signal, 24, 1831–40.

Côme S, Carmichael PH, Verreault R, et al. (2012). Nonsteroidal anti-inflammatory drug use and the risk of cognitive impairment and Alzheimer’s disease. Alzheimers Dement, 8, 219–26.

Dai Y-C, Zhou L-W, Cui B-K, et al. (2010). Current advances in enforcement of artifact formation through solvent extraction method development. J Chromatogr A, 1148, 1–7.

Dasgupta A, Lafontan M, Despres JP, et al. (2001). Lard adipose tissue as an endocrine organ: adiponectin (a cytokine with insulin-sensitising activity) and adipose tissue glucose transporters. Diabetologia, 44, 627–31.

Diana R, Sironi M, Zucchi S, et al. (2012). Consumption of a mushroom-based food product improves human cognitive function. Nutr Neurosci, 15, 123–8.

Diniz O, Gomes-Neto M, de Melo AFG, et al. (2009). Antioxidant and anti-inflammatory activities of a polysaccharide-rich fraction from the mushroom Cortinarius infractus. J Ethnopharmacol, 125, 362–71.

Dluhy GA, Yamamoto Y, Doohan M, et al. (2002). Alzheimer, Parkinson, Huntington, and ALS: common biological mechanisms. Neurobiol Aging, 23, 1019–32.

Dunnett SC, McIlwain B, Gordon WH, et al. (2005). Flavonoids inhibit acetylcholinesterase and alter immediate-early gene expression. J Nutr, 135, 1727–30.

Dunst J, Snow J, Ahmed S, et al. (2005). An antioxidant that induces an increase in brain levels of acetylcholine. J Neurosci, 25, 11349–56.

Dural S, Yagiz M, Yesilada E, et al. (2010). Effect of dietary supplementation with Ginkgo biloba extract on markers of oxidative stress and cognition in experimental cognitive impairment in rats. Eur J Nutr, 53, 345–53.

Dural S, Yagiz M, Yesilada E, et al. (2010). Effect of dietary supplementation with Ginkgo biloba extract on markers of oxidative stress and cognition in experimental cognitive impairment in rats. Eur J Nutr, 53, 345–53.

Ezell J, Stromanstchik M, Stromanstchik A, et al. (2012). A collaborative approach to unraveling the mechanism of action of mushrooms. J Nat Prod, 75, 157–62.

Essa MM, Vijayan RK, Castellano-Gonzalez G, et al. (2012). Neuroprotective effect of natural products against Alzheimer’s disease. Neurochem Res, 37, 1829–42.

Essa MM, Vijayan RK, Castellano-Gonzalez G, et al. (2012). Neuroprotective effect of natural products against Alzheimer’s disease. Neurochem Res, 37, 1829–42.

Gao LW, Li WY, Zhao YL, Wang JW. (2009). The cultivation, bioactive components and pharmacological effects of Ganoderma lucidum. Int J Med Mushrooms, 11, 689–91.

Geissler T, Brandt W, Porzel A, et al. (2010). Acetylcholinesterase inhibitors from the toadstool Cortinarius infractus. Bioorg Med Chem, 18, 2173–7.
Critical Reviews in Biotechnology Downloaded from informahealthcare.com by Library of Health Sci-Univ of Il on 05/29/14

Kawagishi H, Masui A, Tokuyama S, Nakamura T. (2006). Erinacines J
Kawagishi H, Shimada A, Sakamoto H, et al. (1996a). Erinacines E, F, G, H from the mushroom Hericium erinaceum. Phytochem, 32, 175–8.

Kawagishi H, Zhuang C. (2008). Compounds for dementia from the mushroom Daldinia concentrica. J Microbiol Biotechnol, 12, 692–4.

Li C, Li Y, Sun HH. (2006). New ganoderic acids, bioactive triterpenoid metabolites from the mushroom Ganoderma lucidum. Nat Prod Res, 20, 985–91.

Liu P, Yin H, Xu Y, et al. (2006). Effects of ginsenoside Rg1 on postimplantation rat and mouse embryos cultured in vitro. Toxicol Vitro, 20, 234–8.

Lu M-K, Cheng J-J, Lai W-L, et al. (2008). Fermented Antrodia cinnamomea extract protects rat PC12 cells from serum deprivation-induced apoptosis: the role of the MAPK family. J Agric Food Chem, 56, 865–74.

Huang N-K, Cheng J-J, Lai W-L, et al. (2005). Current advances in the treatment of Alzheimer’s disease: focused on considerations targeting Aβ and tau. Transl Neurodegener, 1, 21.

Kim JH, Ha HC, Lee MS, et al. (2012). Immunosenescence, inflammation and Alzheimer’s disease. Longevity Healthspan, 1, 8.

Kita T, Takaya Y, Oshima Y. (1998). Scabronines B, C, D and E, strong stimulators of NGF-synthesis from the mushroom Sarcodon scabrosus. Tetrahedron Lett, 35, 1569–72.

Kokubo T, Taniguchi Y, Kanayama M, et al. (2011). Extract of the mushroom Daldinia concentrica. J Microbiol Biotechnol, 21, 67–72.

Kusuboto T, Taniguchi Y, Kanayama M, et al. (2011). Extract of the mushroom Mycoleptodonoides aitchisonii induces a series of anti-oxidative and phase II detoxifying enzymes through activation of the transcription factor Nrf2. Food Chem, 129, 92–9.

Lai CS-W, Yu M-S, Yuen W-H, et al. (2008). Antagonizing beta-amylod peptide neurotoxicity of the anti-aging fungus Ganoderma lucidum. Brain Res, 1190, 215–24.

Lai P-L, Naidu M, Sabaratnam V, et al. (2013). Neurotrophic properties of the Lion’s Mane medicinal mushroom, Hericium erinaceum (Higher Basidiomycetes) from Malaysia. Int J Med Mushrooms, 15, 539–54.

Lee B, Park J, Park J, et al. (2011). Cordyceps militaris improves neurite outgrowth in Neuro2a cells and reverses memory impairment in rats. Food Sci Biotechnol, 20, 1599–608.

Lee EW, Shizuki K, Hosokawa S, et al. (2000). Two novel diterpenoids, erinacines H and I from the mycelia of Hericium erinaceum. Biosci Biotechnol Biochem, 64, 2402–5.

Lee JY, Yoon J, Kim Y, et al. (2002). Two neuroprotective compounds from mushroom Daldinia concentrica. J Microbiol Biotechnol, 12, 692–4.

Lee IK, Yun B, Kim Y, Yoo I. (2002). Two new diterpenoids, erinacines H and I from the mycelia of Hericium erinaceum. Biosci Biotechnol Biochem, 64, 2402–5.

Liu P, Yin H, Xu Y, et al. (2006). Effects of ginsenoside Rg1 on postimplantation rat and mouse embryos cultured in vitro. Toxicol Vitro, 20, 234–8.

Sarca B, D’Ambrosia S, Palumbo R, et al. (2013). Hericenones and erinacines: stimulators of nerve growth factor (NGF) biosynthesis in Hericium erinaceum. Mycology, 1, 92–8.

Ma BJ, Shen JW, Yu HY, et al. (2010). Hericenones and erinacines: stimulators of nerve growth factor (NGF) biosynthesis in Hericium erinaceum. Mycology, 1, 92–8.

Ma B-L, Zhou Y, Li L-Z, Li H-H. (2008). A new cyathane-xylolide from the mushroom Hericium erinaceum. Z Naturforsch, 63b, 1241–2.

Marzocchetti MC, Pagliottti R, Maltese F, et al. (2006a). Neurite outgrowth activity of the mushroom Yamabushitake (Sarcodon cyrneus, cyrneines A and B) against PC12 cells from serum deprivation-induced apoptosis through the activation of adenosine A3 receptors. Life Sci, 79, 252–8.

Ma BJ, Shen JW, Yu HY, et al. (2010). Hericenones and erinacines: stimulators of nerve growth factor (NGF) biosynthesis in Hericium erinaceum. Mycology, 1, 92–8.

Marton KJ, Arthur JSC. (2012). Selective kinase inhibitors as tools for neuroscience research. Neuropharmacol, 63, 1227–37.

Martorana A, Bulati M, Buffa S, et al. (2012). Immunosenescence, inflammation and Alzheimer’s disease. Longevity Healthspan, 1, 8.

Moldavan M, Grygansky AP, Kolotushkina OV, et al. (2007). Neurotrophic and trophic action of Lion’s Mane Mushroom Hericium erinaceum (Bull., Fr.) Pers. (Aphyllophoromycetidae) extracts on nerve cells in vitro. Int J Med Mushrooms, 9, 15–28.

Mori K, Inatomi S, Ouchi K, et al. (2009). Improving effects of the mushroom Yamabushitake (Hericium erinaceum) on mild cognitive impairment: a double-blind placebo-controlled clinical trial. Phytother Res, 23, 367–72.

Mori K, Obara Y, Hirota M, et al. (2008). Nerve growth factor-inducing activity of the mushroom Hericium erinaceum in 1321N1 human astrocytoma cells. Biol Pharm Bull, 31, 1727–32.

Mori K, Obara Y, Moriya T, et al. (2011). Effects of Hericium erinaceum on amyloid β(25–35) peptide-induced learning and memory deficits in mice. Biomed Res, 32, 67–72.

Muszyńska B, Sulkowska-Ziaja K, Wolkowska M, Ekiert H. (2011). Chemical, pharmacological, and biological characterization of the culinary-medicinal honey mushroom, Armillaria mellea (Vahl) P. Kumm. (Agaricomycetidae): a review. Int J Med Mushrooms, 13, 167–75.

Nagai K, Chiba A, Nishino T, et al. (2006). Dilihexoylphosphatidylethanolamine from Hericium erinaceum protects against ER stress-dependent Neuro2a cell death via protein kinase C pathway. J Nutr Biochem, 17, 525–30.

Nakajima Y, Nishida H, Nakamura Y, Konishi T. (2009). Prevention of hydrogen peroxide-induced oxidative stress in PC12 cells by 3,4-dihydroxybenzalacetone isolated from Chaga (Inonotus obliquus (Pers) Pilat). Free Radical Biol Med, 47, 1154–61.

Nishina A, Kimura H, Sekiguchi A, et al. (2006). Lysophosphatidylethanolamine in Grifola frondosa as a neurotrophic activator via activation of MAPK. J Lipid Res, 47, 1434–43.
Critical Reviews in Biotechnology Downloaded from informahealthcare.com by Library of Health Sci-Univ of Il on 05/29/14

Obara Y, Nakahata N, Kita T, et al. (1999). Stimulation of neurotrophic factor secretion from 1321N1 human astrocytoma cells by novel diterpenoids, scabronines A and G. Eur J Pharmacol, 370, 79–84.

Obara Y, Hoshino T, Marcottoli MC, et al. (2007). A novel cythane diterpene, cyrneine A, induces neurite outgrowth in a Rac1-dependent mechanism in PC12 cells. Life Sci, 80, 1699–77.

Obara Y, Kobayashi H, Ohta T, et al. (2001). Scabronine G-methylster enhances secretion of neurotrophic factors mediated by an activation of protein kinase C-zeta. Mol Pharmacol, 59, 1287–97.

Ohta T, Kita T, Kobayashi N, et al. (1998). Scabronine A, a novel diterpene having potent inductive activity of the nerve growth factor synthesis, isolated from the mushroom, Sarcodon scabrosus. Tetrahedron Lett, 39, 6229–32.

Okuyama S, Lam NV, Hatakeyama T, et al. (2004a). Mycelypodonoides aitchisonii affects brain nerve growth factor concentration in newborn rats. Nutr Neurosci, 7, 341–9.

Okuyama S, Sawaasaki E, Yokogoshi H. (2004b). Conductor compounds of phenylpentane in Mycelypodonoides aitchisonii mycelium enhance the release of dopamine from rat brain striatum slices. Nutr Neurosci, 7, 107–11.

Okuyama S, Tashiro K, Lam NV, et al. (2012). Effect of the edible mushroom Mycelypodonoides aitchisonii on transient global ischemia-induced monoamine metabolism changes in rat cerebral cortex. J Med Food, 15, 96–9.

Park H-J, Shim HS, Ahn YH, et al. (2012). Tremella fuciformis enhances the neurite outgrowth of PC12 cells and restores trimethylinduced impairment of memory in rats via activation of CREB transcription and cholinergic systems. Behav Brain Res, 229, 82–90.

Park I-H, Chung S-K, Lee K-B, et al. (2004b). An antioxidant hispidin from the mycelial cultures of Phellinus linteus. Arch Pharmacal Res, 27, 615–18.

Park I-H, Jeon S-Y, Lee H-J, et al. (2004a). A beta-secretase (BACE1) inhibitor hispidin from the mycelial cultures of Phellinus linteus. Planta Med, 70, 143–6.

Park YS, Lee HS, Won MH, et al. (2002). Effect of an exopolysaccharide from the culture broth of Hericium erinaceus on enhancement of growth and differentiation of rat adrenal nerve cells. Cytotechnol, 39, 155–62.

Perry E, Howes MJR. (2011). Medicinal plants and dementia therapy: herbal hopes for brain aging? CNS Neurosci Ther, 17, 683–98.

Phan CW, David P, Naidu M, et al. (2013). Neurite outgrowth stimulatory effects of culinary-medicinal mushrooms and their toxicity assessment using differentiating Neuro-2a and embryonic fibroblast BALB/3T3. BMC Complement Altern Med, 13, 261.

Phan CW, David P, Naidu M, et al. (2009). Functional recovery following crush injury to rat peroneal nerve by aqueous extracts of Lion’s Mane Mushroom Hericium erinaceus (Bull.: Fr) Pers. Pers. (Aphyllophoromycetideae) on the neural cell line NG107-15. Int J Med Mushrooms, 9, 57–65.

Wong KH, Naidu M, David P, et al. (2010). Peripheral nerve regeneration following crush injury to rat peroneal nerve by aqueous extract of medicinal mushroom Hericium erinaceus (Bull.: Fr) Pers. (Aphyllophoromycetideae). Evid Based Complement Alternat Med Article ID, 580752.

Wong KH, Naidu M, David RP, et al. (2009). Functional recovery enhancement following injury to rodent peroneal nerve by lions mane mushroom, Hericium erinaceus (Bull.: Fr) Pers. (Aphyllophoromycetideae). Int J Med Mushrooms, 11, 225–36.

Wong KH, Naidu M, David RP, et al. (2009). Functional recovery enhancement following injury to rodent peroneal nerve by lions mane mushroom, Hericium erinaceus (Bull.: Fr) Pers. (Aphyllophoromycetideae). Int J Med Mushrooms, 11, 225–36.

Wong KH, Naidu M, David RP, et al. (2009). Functional recovery enhancement following injury to rodent peroneal nerve by lions mane mushroom, Hericium erinaceus (Bull.: Fr) Pers. (Aphyllophoromycetideae). Int J Med Mushrooms, 11, 225–36.

Wong KH, Naidu M, David RP, et al. (2009). Functional recovery enhancement following injury to rodent peroneal nerve by lions mane mushroom, Hericium erinaceus (Bull.: Fr) Pers. (Aphyllophoromycetideae). Int J Med Mushrooms, 11, 225–36.

Wong KH, Naidu M, David RP, et al. (2009). Functional recovery enhancement following injury to rodent peroneal nerve by lions mane mushroom, Hericium erinaceus (Bull.: Fr) Pers. (Aphyllophoromycetideae). Int J Med Mushrooms, 11, 225–36.

Wong KH, Naidu M, David RP, et al. (2009). Functional recovery enhancement following injury to rodent peroneal nerve by lions mane mushroom, Hericium erinaceus (Bull.: Fr) Pers. (Aphyllophoromycetideae). Int J Med Mushrooms, 11, 225–36.

Wong KH, Naidu M, David RP, et al. (2009). Functional recovery enhancement following injury to rodent peroneal nerve by lions mane mushroom, Hericium erinaceus (Bull.: Fr) Pers. (Aphyllophoromycetideae). Int J Med Mushrooms, 11, 225–36.
Zhang R, Xu S, Cai Y, et al. (2011a). *Ganoderma lucidum* protects dopaminergic neuron degeneration through inhibition of microglial activation. Evid Based Complement Alternat Med Article ID, 156810.

Zhang W, Liu HT. (2002). MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res, 12, 9–18.

Zhang X-Q, Ip FCF, Zhang D-M, et al. (2011b). Triterpenoids with neurotrophic activity from *Ganoderma lucidum*. Nat Prod Res, 25, 1607–13.

Zhu WW, Liu ZL, Xu HW, et al. (2005). Effect of the oil from *Ganoderma lucidum* spores on pathological changes in the substantia nigra and behaviors of MPTP-treated mice. Di Yi Jun Yi Da Xue Xue Bao, 25, 667–71.

Supplementary material available online
Supplemental Table 1
Supplemental Figures 1–6.